Evidence map›Paper›PMID 31955176›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2020

Mitofusin-2 (Mfn-2) Might Have Anti-Cancer Effect through Interaction with Transcriptional Factor SP1 and Consequent Regulation on Phosphatidylinositol Transfer Protein 3 (PITPNM3) Expression.

Tao Tang, Xuxiong Tao, Xing Bao, Jun Chen, Jingyu Dai, Jinjun Ye, Yukuang Yan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Mitofusin-2: A New Mediator of Pathological Cell Proliferation.Frontiers in cell and developmental biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Tao TangDepartment of General Surgery, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China (mainland).
Xuxiong TaoDepartment of General Surgery, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China (mainland).
Xing BaoDepartment of General Surgery, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China (mainland).
Jun ChenDepartment of General Surgery, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China (mainland).
Jingyu DaiDepartment of General Surgery, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China (mainland).
Jinjun YeDepartment of General Surgery, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China (mainland).
Yukuang YanDepartment of General Surgery, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China (mainland).
Longgang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND The aim of this study was to explore the influence of mitofusin-2 (Mfn-2) on phosphatidylinositol transfer protein 3 (PITPNM3) and tumor growth and the potential mechanism behind the regulation of Mfn-2 on PITPNM3 in hepatic carcinoma cell line SMMC-7721. MATERIAL AND METHODS We obtained promoter sequence of PITPNM3 gene from University of Santa Cruz (UCSC) genomic database, and we predict transcriptional factor of PITPNM3 genes by JASPAR database. Target transcription factor was determined by comparison of binding sites number for promoter. SMMC-7721 cells were transfected with expression plasmid containing Mfn-2, transcription factor gene and PITPNM3. The cells transfected with empty vector were used as control. Real-time polymerase chain reaction was used to determine the mRNA level of target genes. Co-immunoprecipitation (Co-IP) assay was used to determine the interaction between Mfn-2 and target transcription factor. Chromatin immunoprecipitation assay (ChIP) assay was used to determine the binding of transcription factor with PITPNM3 promoter. Tumorigenicity assay was used to compare the effect of Mfn-2, SP1, and PITPNM3 on tumor development. RESULTS SP1 was selected as the target transcriptional factor. In the Co-IP assay, Mfn-2 was shown to interact with SP1. In the ChIP assay Mfn-2 transfection resulted in decreased binding number of SP1 with PITPNM3 promoter. Furthermore, PITPNM3 mRNA levels were significantly increased in SMMC-7721 cells transfected with SP1 but were decreased after transfection with Mfn-2. In nude mice, PITPNM3 and SP1 upregulation lead to larger tumor lump and conversely Mfn-2 upregulation lead to smaller tumor lump. CONCLUSIONS Mfn-2 could suppress expression of PITPNM3 through interaction with transcription factor SP1; Mfn-2 may have anti-tumor activity; SP1 and PITPNM3 may promote tumor development.

Indexed as

AnimalsBinding SitesCalcium-Binding ProteinsCarcinogenesisCCAAT-Enhancer-Binding Protein-betaCell Line, TumorFemaleGene Expression Regulation, NeoplasticGTP PhosphohydrolasesHumansMembrane ProteinsMice, NudeMitochondrial ProteinsPromoter Regions, GeneticProtein BindingRNA, MessengerCalcium-Binding ProteinsCCAAT-Enhancer-Binding Protein-betaCEBPB protein, humanGTP PhosphohydrolasesMembrane ProteinsMFN2 protein, humanMitochondrial ProteinsPITPNM3 protein, humanRNA, MessengerSP1 protein, humanSp1 Transcription Factor

Identifiers

PMID31955176
PMCPMC6988473
OpenAlexW2999909649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.